New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 2, 2014
07:04 EDTOMEROmeros receives FDA approval for Omidria
Omeros announced that the FDA has approved Omidria 1%/0.3% for use during cataract surgery or intraocular lens replacement to maintain pupil size by preventing intraoperative miosis and to reduce postoperative pain. The approval comes with no post-marketing commitments other than the previously agreed study of Omidria for use in pediatric patients, which, if successfully completed, makes the drug eligible for an additional six months of marketing exclusivity in the U.S. With FDA approval of Omidria, Omeros is completing preparations for a late summer/early fall 2014 U.S. product launch.
News For OMER From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
July 6, 2015
07:58 EDTOMEROmeros weakness creates buying opportunity, says Wedbush
After Omeros' stock sank about 23% since June 22, Wedbush notes that on June 25 an article recommended selling Omeros' stock. The firm says that the article based its conclusion on financial parameters suited to a mature, profitable company, rather than one which just launched its first drug, as is the case with Omeros. Wedbush adds that if the selloff in the stock was caused by the article, it recommends buying the shares. It believes that Omeros' fundamentals haven't changed, while the company has potentially significant catalysts this year. Wedbush keeps an Outperform rating on Omeros.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use